More than five million Americans could be eligible for booster shots of the Covid-19 vaccine by late September under the Biden administration’s plan to combat the Delta variant of the virus by giving extra doses eight months after initial vaccinations.

But the plan depends on several crucial steps taking place in the coming weeks. Most important, the Food and Drug Administration would need to decide that third shots are safe and effective for Pfizer-BioNTech and Moderna, the two vaccines that were rolled out first and have been most used.

Pfizer is farther along in submitting data to the F.D.A. that it says supports the use of boosters. Moderna and the National Institutes of Health are still studying whether a half-dose or a full dose would work better for a third shot but expects results soon. Moderna’s chief executive, Stephane Bancel, has said the firm plans to submit its data to the F.D.A. in September.

Administration officials are to announce the strategy at a White House briefing on Wednesday. Nursing home residents, health care workers and emergency workers would probably be first in line, as they were with the initial shots. Other older people would be next, followed by the rest of the general population.

Officials envision giving people the same vaccine they originally received, and using pharmacies as key distribution points.

Administration officials are discouraging people from seeking booster doses on their own, noting that the F.D.A. has yet to rule on their safety and efficacy. They hope to roll out extra shots in an orderly way so people get a booster shot when it is recommended, not simply based on their own fears.

Dr. Danny Avula, the vaccine coordinator for the state of Virginia, said his state has thousands of vaccine providers already in place and can likely manage boosters with much change. “What caused so much of the urgency and frenzy of January through April was the limitations in supply,” he said.

Now, the government has more than 100 million doses stockpiled that could be used for boosters, along with tens of millions more doses that have already been delivered to pharmacies and other locations. Still more supply is scheduled for delivery this fall.

In interviews on Tuesday, hospital officials and doctors were generally supportive of the push for booster shots.

“I think we’re running out of second chances,” said Dr. Matthew Harris, the medical director of the coronavirus vaccination program at Northwell Health, New York’s largest hospital system. “What keeps me up at night is the inevitability of a variant that is not responsive to the vaccine, so if this is how we stay ahead of it, I fully support it.”

Federal officials envision offering additional shots to recipients of the single dose Johnson & Johnson vaccine, as well as those who got Moderna or Pfizer. But the government only began offering that vaccine in March and only 14 million people have gotten it. By comparison, 155 million people have been fully vaccinated with either Pfizer or Moderna.

Data from a Johnson & Johnson clinical trial in which participants were given two doses is likely to be submitted to the F.D.A. later this month and is expected to guide the government’s recommendation on that vaccine.

At Wednesday’s briefing, administration officials plan to make the case that a booster strategy is essential even if it is must be amended as more data comes in. They are expected to present data showing that vaccine efficacy is declining against Covid infections overall even though unvaccinated people still make up the vast majority of those who become seriously ill or are hospitalized due to Covid.

The administration is worried that without boosters, more vaccinated people could suffer serious Covid disease in the coming months because of a dual trend: the more forceful impact of the Delta variant and waning in the vaccines’ protection.

Data from the Israeli Ministry of Health is being viewed as a warning sign. It suggests protection from coronavirus infection during June and July has dropped in proportion to the length of time since an individual was vaccinated. According to one data set, the Pfizer vaccine’s efficacy against severe disease has fallen to 55 percent for people 65 or older who were vaccinated in January. But the margins for error were wide and experts said other data appeared less worrisome.

Source: NYT

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

PICS: Maskless Italian PM Mario Draghi Lectures Masked Middle School Children… on Masks

Italian Prime Minister Mario Draghi appeared maskless in front of masked children…

Poll: Most Say lllegal Immigration Getting ‘Worse,’ Will Be ‘Important’ Issue in Midterms

Most voters believe illegal immigration is getting “worse” and will be an…

Show Trial Mistrial: January 6 Chair Says No Criminal Referral of Trump, After All; Liz Cheney Disagrees

Rep. Bennie Thompson (D-MS), chair of the January 6 Committee, said Monday…

Embattled Federal Reserve pick Raskin withdraws nomination

WASHINGTON >> Sarah Bloom Raskin withdrew her nomination today to a position…